meta_pixel
Tapesearch Logo
Log in
America Dissected

Big Pharma’s big fraud with Dr. Aaron Kesselheim

America Dissected

Incision Media LLC

Politics, News, Society & Culture

4.64.4K Ratings

🗓️ 27 July 2021

⏱️ 36 minutes

🧾️ Download transcript

Summary

Abdul dissects the FDA’s disastrous decision to approve the new Alzheimer’s drug aducanumab despite the evidence that it fails to improve symptoms—and its aftermath and implications for the future of Big Pharma. He speaks with Professor Aaron Kesselheim, a prescription drug policy expert and a former member of the FDA Advisory Panel, who resigned at the FDA ignored the panel’s overwhelming opposition to approve it the drug. Take Crooked's listener survey: crooked.com/survey For a transcript of this episode, please visit crooked.com/americadissected.

Transcript

Click on a timestamp to play from that location

0:00.0

New data show that U.S. life expectancy fell dramatically in 2020.

0:11.7

It fell three years among Latinx Americans, 2.9 years among black Americans, and a year

0:15.8

and a half overall.

0:17.8

Prince's President Emmanuel Macron announced a plan that will require vaccine verification

0:21.7

for access to restaurants, bars, and government buildings across the nation.

0:26.0

1.7 million French residents signed up for vaccines the next day.

0:30.8

The U.S. surgeon general issued the first surgeon general's advisory of his tenure, calling

0:35.0

misinformation a critical public health threat as the White House battles with Facebook over

0:39.2

their role in spreading lies about the vaccine.

0:42.3

This is America Dissected.

0:43.3

I'm your host, Dr. Abdul-Lasayad.

0:50.6

A few weeks ago, acting head of the FDA, Janet Woodcock, made an unprecedented announcement.

0:56.0

Tonight, the acting head of the FDA, calling for an Inspector General's investigation into

1:00.3

approval of Adjuham, the first Alzheimer's drug in decades.

1:04.8

This investigation is the latest in a long line of unprecedented events having to do with

1:09.3

Alzheimer's drug, adjukanymap, or adjuham, as it's marketed by its manufacturer, biogen.

1:15.4

Adjuham poses a Rubicon moment for the FDA, health insurers, providers, and pharma in the

1:20.4

U.S.

1:21.4

forced regulators, doctors, and the public to ask basic questions about the FDA's approval

1:26.4

process.

1:27.4

How little is too little scientific evidence to allow a drug with serious side effects to

1:30.9

be marketed and sold to the American public?

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Incision Media LLC, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Incision Media LLC and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2025.